In Brief: Ex-Bard execs' trial
This article was originally published in The Gray Sheet
Executive Summary
Ex-Bard execs' trial: Jury deliberation in the conspiracy case against five former Bard officials begins Aug. 17. The five remaining defendants in the trial -- former Bard CEO George Maloney, former Bard Group Vice President David Prigmore, former USCI President John Cvinar, former USCI Director of Regulatory Affairs and Quality Assurance Lee Leichter and former USCI Director of Regulatory Affairs Kenneth Thurston -- are facing criminal conspiracy charges related to alleged actions such as failing to make needed premarket filings to FDA, lying to the agency in the course of obtaining device approvals and failing to report injuries resulting from product failures. Closing arguments in the case were presented Aug. 15-16. The ex-Bard officials' lawyers rested their case without presenting a defense ("The Gray Sheet" Aug. 14, p. 33)...
You may also be interested in...
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.